HomeORGANIZATION
ORGANIZATION

Interview: Ex-Astellas Boss Takenaka Urges Mid-Size Makers to Be More Open to Academia in Pathological Research
(Aug.18.2016)

As Japanese drug makers see it increasingly difficult to count on their off-patent brands, mid-sized players are readopting the business model of making profits while their drugs are on patent. Many firms seem to be in-licensing drug candidates as a way to buy time for reinforcing their drug discovery research. Toichi Takenaka, former chairman of Astellas Pharma who now heads the Japan Health Sciences Foundation, sat with Jiho to talk about the future vision of research-oriented mid-sized makers ...
(LOG IN FOR FULL STORY)

News Calendar